These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 4005562)

  • 1. Topographical analysis of nucleus accumbens sites at which cholecystokinin potentiates dopamine-induced hyperlocomotion in the rat.
    Crawley JN; Hommer DW; Skirboll LR
    Brain Res; 1985 Jun; 335(2):337-41. PubMed ID: 4005562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of cholecystokinin octapeptide and dopamine on nucleus accumbens neurons.
    White FJ; Wang RY
    Brain Res; 1984 May; 300(1):161-6. PubMed ID: 6145498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral evidence for cholecystokinin modulation of dopamine in the mesolimbic pathway.
    Crawley JH
    Prog Clin Biol Res; 1985; 192():131-8. PubMed ID: 4080706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo electrochemical analysis of cholecystokinin-induced inhibition of dopamine release in the nucleus accumbens.
    Lane RF; Blaha CD; Phillips AG
    Brain Res; 1986 Nov; 397(1):200-4. PubMed ID: 3801862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCK-8 injected into the nucleus accumbens attenuates the supersensitive locomotor response to apomorphine in 6-OHDA and chronic-neuroleptic treated rats.
    Weiss F; Ettenberg A; Koob GF
    Psychopharmacology (Berl); 1989; 99(3):409-15. PubMed ID: 2574480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonists of central and peripheral behavioral actions of cholecystokinin octapeptide.
    Crawley JN; Stivers JA; Hommer DW; Skirboll LR; Paul SM
    J Pharmacol Exp Ther; 1986 Feb; 236(2):320-30. PubMed ID: 3003339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of cholecystokinin (CCK-8) on dopamine-containing nerve terminals in the caudate nucleus and nucleus accumbens of the anesthetized rat: an in vivo electrochemical study.
    Gerhardt GA; Friedemann M; Brodie MS; Vickroy TW; Gratton AP; Hoffer BJ; Rose GM
    Brain Res; 1989 Oct; 499(1):157-63. PubMed ID: 2804664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microinjections of nanogram amounts of sulfated cholecystokinin octapeptide into the rat nucleus accumbens attenuates brain stimulation reward.
    Vaccarino FJ; Koob GF
    Neurosci Lett; 1984 Nov; 52(1-2):61-6. PubMed ID: 6098878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological and mechanistic studies of cholecystokinin-facilitated [3H]dopamine efflux from rat nucleus accumbens.
    Vickroy TW; Bianchi BR
    Neuropeptides; 1989 Jan; 13(1):43-50. PubMed ID: 2466220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of cholecystokinin on the in vivo release of newly synthesized [3H]dopamine from the nucleus accumbens of the rat.
    Voigt MM; Wang RY; Westfall TC
    J Neurosci; 1985 Oct; 5(10):2744-9. PubMed ID: 4045551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specificity of nucleus accumbens to activities related to cholecystokinins in rats.
    Katsuura G; Itoh S; Hsiao S
    Peptides; 1985; 6(1):91-6. PubMed ID: 3991366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholecystokinin potentiates dopamine-mediated behaviors: evidence for modulation specific to a site of coexistence.
    Crawley JN; Stivers JA; Blumstein LK; Paul SM
    J Neurosci; 1985 Aug; 5(8):1972-83. PubMed ID: 4040554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of long-term haloperidol treatment on the responsiveness of accumbens neurons to cholecystokinin and dopamine: electrophysiological and radioligand binding studies in the rat.
    Debonnel G; Gaudreau P; Quirion R; de Montigny C
    J Neurosci; 1990 Feb; 10(2):469-78. PubMed ID: 2137531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opposite actions of CCK-8 on amphetamine-induced hyperlocomotion and stereotypy following intracerebroventricular and intra-accumbens injections in rats.
    Weiss F; Tanzer DJ; Ettenberg A
    Pharmacol Biochem Behav; 1988 Jun; 30(2):309-17. PubMed ID: 3174761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does cholecystokinin potentiate dopamine action in the nucleus accumbens?
    Wang RY; Hu XT
    Brain Res; 1986 Aug; 380(2):363-7. PubMed ID: 3756487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity: evidence for rostral-caudal differences in accumbens CCK function.
    Vaccarino FJ; Rankin J
    Behav Neurosci; 1989 Aug; 103(4):831-6. PubMed ID: 2765186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway.
    Crawley JN
    J Neurosci; 1992 Sep; 12(9):3380-91. PubMed ID: 1527584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo release of dopamine in the nucleus accumbens of the rat: modulation by cholecystokinin.
    Voigt MM; Wang RY
    Brain Res; 1984 Mar; 296(1):189-93. PubMed ID: 6324955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of CCK8 and of the CCKB-selective agonist BC264 on extracellular dopamine content in the anterior and posterior nucleus accumbens: a microdialysis study in freely moving rats.
    Ladurelle N; Keller G; Roques BP; Daugé V
    Brain Res; 1993 Nov; 628(1-2):254-62. PubMed ID: 8313154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral evidence for the involvement of endogenous opioids in the interaction between cholecystokinin and brain dopamine systems.
    Király I; Van Ree JM
    Neurosci Lett; 1987 Mar; 74(3):343-7. PubMed ID: 3561887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.